A Study to Learn About the Outcomes Between Study Medicines, Enzalutamide and Darolutamide Among Men With Metastatic Castration Sensitive Prostate Cancer (mCSPC)
← catalyst calendarNCT07779590 · readout in 85 d
Sponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
—
Status
Not yet recruiting
Study type
Observational
Enrollment
4,700estimated
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-21
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-09-01 | estimated | When the study began enrolling |
| Primary completion | 2026-11-15 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-11-15 | estimated | The whole study's end, after follow-up |
| First posted | 2026-08-21 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-21 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Metastatic Castration Sensitive Prostate Cancer (mCSPC)
Interventions
- Drug: darolutamide plus androgen deprivation therapy
- Drug: Enzalutamide plus androgen deprivation therapy
Primary outcome
what the primary-completion date above is the date OFMedian Real-world time to next treatment (rwTTNT)
measured time from index date to the start of the next treatment course (August 1, 2022- March 31, 2026)
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed